证券日报网讯博苑股份（301617）9月19日在互动平台回答投资者提问时表示，截至2025年9月10日，公 司股东总户数为10，228户。 ...

格隆汇9月19日丨博苑股份(301617.SZ)在投资者互动平台表示，公司4000吨/年无机碘化物生产项目正在 建设过程中，碘化锂产品尚未量产，具体生产和销售情况请以公司后续披露的定期报告为准。 ...

Core Viewpoint - The stock of Shandong Boyuan Pharmaceutical Chemical Co., Ltd. has shown significant price increases this year, with a year-to-date rise of 108.17% as of September 15, 2023, despite a recent decline in trading [1][2]. Group 1: Company Overview - Shandong Boyuan Pharmaceutical Chemical Co., Ltd. was established on August 6, 2008, and is located in Shouguang City, Shandong Province [2]. - The company specializes in the research, production, and sales of fine chemicals, including organic iodides, inorganic iodides, precious metal catalysts, luminescent materials, and hexamethyldisilazane [2]. - The revenue composition of the company includes 74.56% from iodides, 12.79% from specialty functional chemicals, 9.94% from trading, and 2.72% from other sources [2]. Group 2: Financial Performance - For the first half of 2025, the company achieved operating revenue of 747 million yuan, representing a year-on-year growth of 7.39%, while the net profit attributable to shareholders decreased by 19.09% to 99.04 million yuan [2]. - The company has distributed a total of 88.41 million yuan in dividends since its A-share listing [3]. Group 3: Stock Performance and Trading Activity - As of September 15, 2023, the stock price was 80.64 yuan per share, with a market capitalization of 10.777 billion yuan [1]. - The stock has experienced a trading volume of 1.17 billion yuan, with a turnover rate of 4.25% [1]. - The stock has appeared on the "Dragon and Tiger List" four times this year, with the most recent net buy of 51.18 million yuan on September 9, 2023 [1].

证券日报网讯 博苑股份9月12日发布公告，在公司回答调研者提问时表示，公司现有产品无机碘化物主 要包括碘化钾、碘酸钾、碘化钠、氢碘酸、碘化亚铜等，主要应用于医药、农药、饲料、光电材料等领 域。目前公司有机碘化物产品三甲基碘硅烷作为有机合成中的官能团保护剂，主要应用于医药领域（如 头孢类、大环内酯类抗生素生产）等。 （编辑 袁冠琳） ...

Core Viewpoint - The company is expanding its business into hexamethyldisilazane products based on the common needs of its existing pharmaceutical clients and its advantages in resource utilization and technology [1] Group 1: Business Expansion - The company has identified a demand from its existing pharmaceutical clients for hexamethyldisilazane products, leading to its business expansion in this area [1] - The expansion into hexamethyldisilazane requires minimal additional investment and offers cost advantages in raw material acquisition [1] Group 2: Resource Utilization - The company has established a collaborative foundation in resource utilization, including operational qualifications, incineration facilities, shared equipment, production sites, practical experience, and a professional team [1] - The company is leveraging its strengths in waste recovery to extend its operations from organic solvent recovery to the recycling of siloxanes [1] Group 3: Market Positioning - Both iodides and hexamethyldisilazane are functional additives used in the pharmaceutical chemical process, sharing similar application scenarios and functional characteristics [1] - The company is strategically positioning itself in the market by utilizing its existing iodide products as a basis for the new hexamethyldisilazane product line, aligning with market demand and competitive landscape [1]

New Stock Issuance - YouSheng Co., Ltd. (Securities Code: 732418) issued shares at a price of 46.36 RMB on September 12, 2025[1] - *ST Tianmao (Securities Code: 000627) has a cash option declaration period from September 15 to September 19, 2025[1] - *ST Zitian (Securities Code: 300280) enters the delisting arrangement period starting September 15, 2025[1] Trading Alerts - Hangke Technology (Securities Code: 688006) reported severe abnormal fluctuations on September 11, 2025[1] - Shanghai Electric Power (Securities Code: 600021) had a trading volume of 8,487 on September 10, 2025[1] - Tianji Co., Ltd. (Securities Code: 002759) reported a trading volume of 8,705 on September 10, 2025[1] Abnormal Fluctuations - ST Lingnan (Securities Code: 002717) reported a trading volume of 7,965 on September 10, 2025[3] - ST Huaxi (Securities Code: 002630) reported a trading volume of 9,579 on September 11, 2025[3] - ST Jianye (Securities Code: 600381) reported a trading volume of 5,420 on September 3, 2025[3]

Group 1: Company Overview - The company is Shandong Boyuan Pharmaceutical Chemical Co., Ltd., with stock code 301617 and abbreviation Boyuan Shares [1]. - The investor relations activity took place on September 11, 2025, in the Boyuan Shares conference room [2]. Group 2: Key Products and Applications - Iodine and its derivatives are crucial raw materials in medical, agricultural, industrial, and nutritional fields, widely used in various product formulations [2]. - The downstream application structure of iodine includes three core areas: X-ray contrast agents, pharmaceutical manufacturing, and LCD panel manufacturing, which together account for approximately 63% of global consumption [2]. - Major iodine production is concentrated in Chile, Japan, and the USA, with these three countries expected to account for 88% of global production [3]. Group 3: Product Specifics - The company’s inorganic iodide products include potassium iodide, potassium iodate, sodium iodide, hydriodic acid, and cuprous iodide, primarily used in pharmaceuticals, pesticides, feed, and optoelectronic materials [4]. - The company’s organic iodide product, trimethylsilyl iodide, is used as a protecting group in organic synthesis, particularly in the production of antibiotics [4]. Group 4: Business Development and Future Plans - Currently, the company has not achieved sales in the solid-state battery sector but is exploring new application scenarios and conducting feasibility studies [4]. - The expansion into hexamethyldisilazane products is driven by existing pharmaceutical customer needs and the company's resource utilization capabilities [5]. - The company leverages its expertise in waste recovery to develop hexamethyldisilazane products, which share similar application scenarios and functional characteristics with iodides [5].

（文章来源：证券日报） 证券日报网讯博苑股份9月11日在互动平台回答投资者提问时表示，截至2025年9月10日，公司股东总户 数为10，228户。 ...

证券日报网讯博苑股份（301617）9月11日在互动平台回答投资者提问时表示，公司碘化物产品，目前 主要应用于医药、化工、光电材料、饲料、食品等领域，暂未在固态电池领域实现销售。公司将围绕自 身主营业务，积极探索新产业（300832）领域应用场景，开展可行性研究，并在稳妥的基础上探索尝试 新业务领域。 ...

Core Viewpoint - The company, Boyuan Co., Ltd. (301617.SZ), is currently focusing on its main business of iodides, which are primarily used in pharmaceuticals, chemicals, optoelectronic materials, feed, and food sectors, and has not yet achieved sales in the solid-state battery field [1] Group 1 - The company's iodide products are mainly applied in various industries including pharmaceuticals, chemicals, optoelectronic materials, feed, and food [1] - The company has not yet realized sales in the solid-state battery sector [1] - The company plans to explore new industry applications and conduct feasibility studies while maintaining a cautious approach [1]